Futura Medical Share Discussion Threads

[lbo] 05/5/2023 15:34

Again just more and more false and misleading claims from Petroc the proven multi-ID ramper! Perhaps he should attempt to defame ADVFN again for how they manage their platform and its functionality! Would directing ADVFN users to a competitor platform also be objectionable?

petroc poven a multi-ID liar yet again

petroc - 28 Feb 2023 - 11:24:16 - 16672 of
17500 I have one name here - Petroc, and Bucolic on LSE

petroc - 18 Mar 2023 - 16:54:59 - 17374 of 17502

LSE is the bb to visit if you want decent chat about FUM




Just like UK HCP website that was advertised by Petroc on bulletin boards also says:

˜when assessed against internationally accepted criteria for clinical effectiveness (Rosen and Araujo) the efficacy of Eroxon exceeded the minimal clinically important difference’

And the HCP Brochure on the same website references the specific study ˜Minimal clinically Important Difference Rosen et al 2011’

But its clear in that study that the MCID criteria were estimated based on only just on regular adequately controlled and blinded oral only ED studies

The Rosen study also clearly states in its limitations the results have not been replicated in ‘non pharmacologic studies’

And FM71 was cleary a non pharmacologic medical device gel study!

So they are clearly not internationally accepted criteria for ‘non pharmacologi studies’ according to the original reference research paper. Like the medical device gel study FM71. Which was totally uncontrolled, unblinded and ‘prone to bias’ and therefore known to have much higher placebo effect then oral pharmacologic placebos in adequately controlled and blinded studies.

So now its can be claimed that consumers are being ‘Duped’ by the multi-ID ramper advertising the HCP on bulletin boards when the inappropriate MCID comparison is being used to make a indirect cross comparison to non regular inadequately blinded medical device gel studies.



MCIDs were estimated using data from 17 randomized, double-blind, placebo-controlled, parallel-group clinical trials of the phosphodiesterase type 5 inhibitor

limitations

Current analyses were based on 17 clinical trials of tadalafil. Results need to be replicated in studies using other PDE5-Is or in nonpharmacologic intervention studies.

[petroc] 05/5/2023 15:20

Nothing to say about your silly little history changing antics, LiarBO?

[petroc] 05/5/2023 15:19

'any information which in ADVFN's sole opinion is objectionable' Note the word 'sole', LiarBO. It means their opinion, not yours.

[lbo] 05/5/2023 14:26

Again the T&Cs are clear



You agree to not post (or transmit) (i) any information which in ADVFN's sole opinion is objectionable including, without limit, information which is defamatory, obscene, threatening, untrue or in breach of any applicable laws, rules, regulations or market conventions (including, without limit, financial services regulations), (ii) any information which is in breach of any person's rights (including without limit, copyright and confidentiality), (iii) any information or software which contains a virus, cancelbot, Trojan horse, worm or is otherwise harmful or (iv) any information which (in ADVFN's sole opinion) constitutes advertising or (v) any information outside the area designated for posting or (vi) any information or comment which (in ADVFN's sole opinion) is deemed harmful to ADVFN or ADVFN's commercial interests.

[petroc] 05/5/2023 14:23

Clearly LiarBO doesn't know the meaning of defamatory, which means saying or writing bad things about someone WHICH AREN'T TRUE.

Ergo, ‘blame ADVFN, as it's their responsibility. I've asked them frequently to apply the rules, but they ignore it. Probably because lbo has been paying his subscriptions faithfully over the years, he follows one of the mods, and they follow him. A very cosy arrangement’

and:

‘ Could it be because he's paid them 100s of pounds over the years in subscriptions? Could it be because he follows a member of the team, and they follow him’ are not defamatory, because they are true, or were at the time of writing, before LiarBO stopped following them, for reasons I have previously explained.

[lbo] 05/5/2023 14:13

ROFLMAO

petroc - 21 Jan 2022 - 18:03:42 - 10541 of 10710
What is not to love Eroxon /MED3000 - HERE ARE THE FACTS

- Patent application in progress using patent lawyers - COMING SOON



And where is the enforceable patent you said was ‘FACTS’ ‘coming soon’ over a year ago now!?

I wonder why Futura didn’t just use a more simple ˜validated handheld thermal imaging’ method to measure the evaporative cooling effect!?



˜Lillys CIALIS patent claims extending to physiologically acceptable salt found invalid for overbreadth and insufficiency’



˜TPR100 gave similar results to the gold standard, Voltarol 2% gel’



Voltarol Emugel vehicle gel is made of the same ˜evaporative cooling’ ingredients as in Eroxon. The voltarol vehicle is even off patent same as Dermasys is!

carbomer,
isopropyl alcohol,
propylene glycol,
water



Perrigo Company plc today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now available in the U.S. nationwide



The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moisturizing properties and fragrance.



A key element of Futura Medicals strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect

[lbo] 05/5/2023 14:04

You have made defamatory comments against ADVFN on their own platform IMHO!

Their T&Cs are clear



[e-mail]


petroc - 08 Aug 2022 - 14:58:12 - 12606 of 18722

‘blame ADVFN, as it's their responsibility. I've asked them frequently to apply the rules, but they ignore it. Probably because lbo has been paying his subscriptions faithfully over the years, he follows one of the mods, and they follow him. A very cosy arrangement’

petroc - 16 Jun 2022 - 14:28:05 - 12176 of 18721

‘ Could it be because he's paid them 100s of pounds over the years in subscriptions? Could it be because he follows a member of the team, and they follow him’

[lbo] 05/5/2023 13:58

Yes you have used ‘obscene’ language and made defamatory posts that are false! Clearly breaching the ADVFN T&Cs

[e-mail]



After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction



Eroxon was the placebo used in FM57




Just like Flexiseq. Med3000 was also just the placebo in the FM57 study.Therefore like with Flexiseq. Futura had initially believed Med3000 had no therapeutic effect. The FM57 study did not set out to measure the efficacy of Med3000. The ASA will therefore consider that its reported effectiveness by Futura was a ‘false positive’ ‘post-hoc finding’

The CAP Code required that objective claims, including medical claims for a CE-marked medical device, be backed by evidence

a certified Class IIb medical device. We understood that the device certification was granted by a body within the European Member States that had been designated to carry out conformity assessments under the Medical Device Directive

had been used as the placebo treatment in that study, and therefore the researcher had initially believed it had no therapeutic effect. The trial did not set out to measure the efficacy

its reported effectiveness by the advertiser was a post-hoc finding due to the risk of that being a false positive finding

We were also concerned that there was not an adequate placebo control in the trial. We, therefore, considered that the study did not provide adequate evidence for the claim ‘clinically proven’

[petroc] 05/5/2023 13:53

Where's your normal two up-votes gone, LiarBO? Lol!

Btw, claiming that I have breached the T&Cs and copy/pasting an extract which clearly I've not breached just makes you look even more foolish than you usually do. Besides, if I had breached them, you would no doubt have referred me to your friends, the moderators, who follow you and you used to follow, until I pointed it out and you quickly stopped following them. You obviously don't believe I've breached anything because you've been quick to report any of my posts in the past which you've taken umbrage with! You're just a lying and scheming stock basher, constantly trying to manipulate the share price by spreading baseless and misleading propaganda about FUM. Obviously you don't have anything real to use which is why you keep referring to Flexiseq and Ivermectin, and any other manner of stuff which have nothing to do with Eroxon.

[lbo] 05/5/2023 13:32

‘Dont be deceived by junk science’



Make a complaint

Quickly and easily submit your ad complaint with us online.

You can complain to us by:

completing our online complaints form (click continue below),




You can complain to us if:

you're a member of the public, you work for a competitor or you’re associated with a group with an obvious interest

[lbo] 05/5/2023 13:29

Just like UK HCP website that was advertised by Petroc on bulletin boards also says:

‘when assessed against internationally accepted criteria for clinical effectiveness (Rosen and Araujo) the efficacy of Eroxon exceeded the minimal clinically important difference’

And the HCP Brochure on the same website references the specific study ‘Minimal clinically Important Difference Rosen et al 2011’

But its clear in that study that the MCID criteria were estimated based on only just on regular adequately controlled and blinded oral only ED studies

The Rosen study also clearly states in its limitations the results have not been replicated in ‘non pharmacologic studies’

And FM71 was cleary a non pharmacologic medical device gel study!

So they are clearly not internationally accepted criteria for ‘non pharmacologi studies’ according to the original reference research paper. Like the medical device gel study FM71. Which was totally uncontrolled, unblinded and ‘prone to bias’ and therefore known to have much higher placebo effect then oral pharmacologic placebos in adequately controlled and blinded studies.

So now its can be claimed that consumers are being ‘Duped’ by the multi-ID ramper advertising the HCP on bulletin boards when the inappropriate MCID comparison is being used to make a indirect cross comparison to non regular inadequately blinded medical device gel studies.



MCIDs were estimated using data from 17 randomized, double-blind, placebo-controlled, parallel-group clinical trials of the phosphodiesterase type 5 inhibitor

limitations

Current analyses were based on 17 clinical trials of tadalafil. Results need to be replicated in studies using other PDE5-Is or in nonpharmacologic intervention studies.

[lbo] 05/5/2023 12:01

So if a patent does not proceed to grant or any patent rights are determined to be unenforceable the royalties may be reduced?Is this clause in the Cooper agreement?https://futuramedical.com/media/2187/admission_doc.pdf a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product. The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[lbo] 05/5/2023 11:50

ROFLMAO

And where is the enforceable patent you said was ‘FACTS’ ‘coming soon’ over a year ago now!?

‘Other variable considerations such as milestone payments and royalties are not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. In management’s opinion, that will be when the Groups customer confirms that the milestone has been met or that a royalty is due’


Its nearly a wonder why lombard are dumping shares!!!

But if Futura is so cheap at a £150 Mkt Cap. Why dont they just exercise them all and go over 30% and takeover the whole company at 40p!?

Or maybe thats why Lombard is dumping millions of shares on the market so they are not forced into making an offer for Futura at 40p when their average price is still well below 20p LOL



Lombard Odier will receive a total of 10,937,500 warrants to subscribe for further new Ordinary Shares at a price of 40 pence per share, exercisable until the fifth anniversary of their issue, in respect of its participation in the Subscription.

[petroc] 05/5/2023 11:47

LiarBO still peddling old news, I see. His first link above to finance.yahoo included this statement:

'Because Futura Medical isn't currently generating revenue, we consider it an early-stage business.'

Got news for you, LiarBO!

Not forgetting 'Current cash runway extends beyond initial Eroxon® launches expected over the next year and expected US regulatory approval in 2023.'

Just give up, LiarBO. Everyone sees straight through your lies and anti-FUM propaganda.

[lbo] 05/5/2023 10:57

Its now May 2023 and 5 months later! LOL



at December 2022, Futura Medical had cash of UK£4.0m

‘Therefore, from December 2022 it had roughly 7 months of cash runway. To be frank, this kind of short runway puts us on edge’




Product revenue represents net invoice less estimated volume discounts, which are considered to be variable consideration and include significant estimates. Other variable considerations such as milestone payments and royalties are not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. In management’s opinion, that will be when the Groups customer confirms that the milestone has been met or that a royalty is due



a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product.

The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[petroc] 05/5/2023 10:54

· Cash resources of £4.03 million including

· £1.02 million tax credit refund due mid 2023

· Current cash runway extends beyond initial Eroxon® launches expected over the next year and expected US regulatory approval in 2023.



James Barder, Chief Executive Officer, Futura Medical said: "2022 has been a year of significant progress as we have moved steadily towards the initial launch of Eroxon® which I am now delighted to say commenced in March 2023. This is a milestone achievement for the Company and a testimony to the dedication, tenacity and hard work of a small, loyal and highly professional team at Futura. We are proud and excited for Eroxon® to have now commenced launch for what we believe will become the world's first fast-acting clinically proven topical gel treatment for ED available without the need of a doctor's prescription.